Longeveron Inc. (NASDAQ:LGVN) Sees Significant Decrease in Short Interest

Longeveron Inc. (NASDAQ:LGVN) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 979,704 shares, a decrease of 26.6% from the December 15th total of 1,334,145 shares. Currently, 5.2% of the shares of the company are short sold. Based on an average daily trading volume, of 372,571 shares, the short-interest ratio is presently 2.6 days. Based on an average daily trading volume, of 372,571 shares, the short-interest ratio is presently 2.6 days. Currently, 5.2% of the shares of the company are short sold.

Longeveron Stock Down 2.1%

Shares of Longeveron stock traded down $0.01 on Friday, hitting $0.55. The stock had a trading volume of 75,911 shares, compared to its average volume of 229,422. The stock has a market cap of $11.77 million, a price-to-earnings ratio of -0.52 and a beta of 0.21. The business’s 50 day moving average is $0.60 and its two-hundred day moving average is $0.87. Longeveron has a twelve month low of $0.49 and a twelve month high of $1.92.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). Longeveron had a negative net margin of 1,485.25% and a negative return on equity of 138.44%. The firm had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.29 million. As a group, equities analysts predict that Longeveron will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $6.50.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.